Back to top

Image: Bigstock

GSK Wins FDA Approval for Nuvalent-Acquired Nelkarmi in Lung Cancer

Read MoreHide Full Article

Key Takeaways

  • GSK secured FDA approval for Nelkarmi in advanced ALK-positive NSCLC after prior targeted therapies.
  • Nelkarmi's approval was supported by positive data from the phase I/II ALKOVE-1 study.
  • GSK advances Nelkarmi in the phase III ALKAZAR study for first-line ALK-positive NSCLC patients.

GSK plc (GSK - Free Report) announced that the FDA has granted accelerated approval to Nelkarmi (neladalkib), a next-generation anaplastic lymphoma kinase (ALK) inhibitor for the treatment of certain patients with lung cancer. The approval came ahead of the regulatory authority's Nov. 27, 2026 target action date.

The drug is approved for adults with locally advanced or metastatic ALK-positive non-small cell lung cancer (NSCLC) whose disease has progressed following treatment with existing ALK-targeted therapies, with or without chemotherapy.

GSK added Nelkarmi to its late-stage pipeline through the acquisition of Nuvalent in June 2026.

The approval strengthens GSK's oncology portfolio and marks the company's second FDA approval for a lung cancer treatment in 2026. Earlier, in July, the FDA approved Jideytro (zidesamtinib) for previously treated adults with advanced or metastatic ROS1-positive NSCLC.

Year to date, GSK’s shares have risen 4% compared with the industry’s 7.7% growth.

Zacks Investment Research
Image Source: Zacks Investment Research

FDA Approval Based on GSK’s ALKOVE-1 Study Data

The FDA’s approval of Nelkarmi was supported by data from the phase I/II ALKOVE-1 study, which evaluated the drug in patients previously treated with ALK inhibitors, with or without chemotherapy.

Nelkarmi achieved an overall response rate of 49% in patients previously treated with one ALK inhibitor and 32% in those who had received at least two ALK inhibitors and chemotherapy. More than half of the responders in both groups maintained their responses for at least 12 months.

The drug also showed activity against brain metastases, with intracranial response rates of 55% and 26% in the respective groups. Common adverse effects included liver toxicity, musculoskeletal pain, peripheral neuropathy, swelling and fatigue.

Nuvalent Acquisition Expands GSK's Oncology Pipeline

The Nuvalent acquisition strengthened GSK's growing oncology business by adding a portfolio of targeted therapies for genetically defined forms of NSCLC. Beyond Jideytro and Nelkarmi, the acquired pipeline includes NVL-330, a HER2-targeted therapy that is being evaluated in phase I studies for HER2-altered NSCLC.

GSK is evaluating Nelkarmi in the ongoing phase III ALKAZAR study in previously untreated patients with ALK-positive NSCLC, as well as in other solid tumors.

GSK’s Zacks Rank & Stock to Consider

GSK currently carries a Zacks Rank #3 (Hold).

Some better-ranked stocks in the biotech sector are Amneal Pharmaceuticals (AMRX - Free Report) , currently sporting a Zacks Rank #1 (Strong Buy), and AC Immune (ACIU - Free Report) and Adaptive Biotechnologies (ADPT - Free Report) , carrying a Zacks Rank #2 (Buy) each. You can see the complete list of today’s Zacks #1 Rank stocks here.

Over the past 30 days, earnings per share estimates for Amneal Pharmaceuticals have increased from $1.03 to $1.06 for 2026. Over the same period, estimates for 2027 earnings per share have risen from $1.16 to $1.21. AMRX’s shares have jumped 67.6% year to date.

Amneal Pharmaceuticals’ earnings beat estimates in each of the trailing four quarters, delivering an average surprise of 27.21%.

Over the past 30 days, loss per share estimates for AC Immune have narrowed from 60 cents to 54 cents for 2026. Over the same period, estimates for 2027 earnings per share have increased from 17 cents to 43 cents. ACIU’s shares have declined 32.8% year to date.

AC Immune’s earnings beat estimates in each of the trailing four quarters, with an average surprise of 37.79%.

Over the past 30 days, loss per share estimates for Adaptive Biotechnologies have narrowed from 55 cents to 39 cents for 2026. Over the same period, estimates for 2027 loss per share have also improved from 17 cents to 3 cents. ADPT’s shares have surged 75.4% year to date.

Adaptive Biotechnologies’ earnings beat estimates in each of the trailing four quarters, delivering an average surprise of 53.62%.

Published in